Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
← catalyst calendarSponsored by Azitra Inc. (industry) · AZTR — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
6actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-16 | actual | When the study began enrolling |
| Primary completion | 2026-07-07 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-07 | actual | The whole study's end, after follow-up |
| First posted | 2023-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Netherton Syndrome
Intervention
- Drug: ATR12-351 — also filed as ATR-12
Primary outcome
what the primary-completion date above is the date OFAdverse events
measured 84 days
Permalink · AZTR's whole pipeline · Catalyst calendar · Every registered study · What changed